MSL
ACOR

Mackay Shields LLC’s Acorda Therapeutics ACOR Stock Holding History

Mackay Shields LLC’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-170
Closed -$271K – 1540
2019
Q1 		$271K Buy
170
+23
+16% +$41.4K ﹤0.01% 1296
2018
Q4 		$274K Sell
147
-15
-9% -$32.6K ﹤0.01% 1264
2018
Q3 		$383K Sell
162
-9
-5% -$27.9K ﹤0.01% 1037
2018
Q2 		$590K Hold
171
– – ﹤0.01% 1062
2018
Q1 		$486K Buy
+171
New +$512K ﹤0.01% 1119

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Mackay Shields LLC's ACOR Position: Q2 2019 in Review

Mackay Shields LLC sold out of Acorda Therapeutics (ACOR) in Q2 2019, closing a stake of 170 shares — an estimated $271K sold.

Mackay Shields LLC first reported a position in ACOR in Q1 2018 and held it in 5 quarters. The position peaked at $590K in Q2 2018. 163 funds tracked by Wall St. Rank hold ACOR as of Q2 2019.

  • Mackay Shields LLC reported no remaining Acorda Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Mackay Shields LLC sold 170 Acorda Therapeutics shares in Q2 2019, an estimated $271K.
  • Mackay Shields LLC first reported a position in Acorda Therapeutics in Q1 2018 and held it in 5 quarters.
  • Mackay Shields LLC's Acorda Therapeutics position peaked at $590K in Q2 2018.
  • 163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2019.

Based on Mackay Shields LLC's 13F filing for Q2 2019, filed 13 Aug 2019.